CM
ARQT icon

Castleark Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Castleark Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.6M Sell
137,420
-156,040
-53% -$3.64M 0.1% 183
2026
Q1 		$6.91M Sell
293,460
-15,970
-5% -$408K 0.23% 108
2025
Q4 		$8.99M Buy
+309,430
New +$7.92M 0.26% 75

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Castleark Management's ARQT Position: Q2 2026 in Review

Castleark Management reduced its Arcutis Biotherapeutics (ARQT) stake by 53% in Q2 2026, selling an estimated $3.64M and leaving 137,420 shares worth $3.6M. The position accounts for 0.1% of the portfolio, ranked #183.

Castleark Management first reported a position in ARQT in Q4 2025 and has held it in 3 quarters since. The position peaked at $8.99M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Castleark Management held 137,420 shares of Arcutis Biotherapeutics worth $3.6M as of Q2 2026.
  • Castleark Management sold 156,040 Arcutis Biotherapeutics shares in Q2 2026, an estimated $3.64M.
  • Arcutis Biotherapeutics made up 0.1% of Castleark Management's portfolio in Q2 2026, its #183 holding.
  • Castleark Management first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • Castleark Management's Arcutis Biotherapeutics position peaked at $8.99M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Castleark Management's 13F filing for Q2 2026, filed 14 Aug 2026.